natgillin/translations-raw huggingface dataset:
The patient or caregiver will be instructed in injection techniques, the keeping of a treatment diary and measures to be taken in case of severe adverse events. 
Bolnik ali negovalno osebje bo poučeno o tehnikah injiciranja, vodenju dnevnika zdravljenja in ukrepih v primeru hudih neželenih učinkov.
You are likely to have more fatty tissue the closer you are to the hip and the further you are from the knee. 
Verjetno je več maščobnega tkiva čim bližje kolku in čim dlje od kolena.
Thighs: Use middle and outer areas where you can pinch up tissue. 
Stegno: Uporabite srednja in zunanja področja, kjer lahko tkivo stisnete in dvignete.
If you do choose to inject your arm yourself, try to pinch up the tissue by placing your upper arm over the back of a chair or brace it against a wall. 
Če se odločite, da si boste zdravilo sami injicirali v roko, poskusite tkivo stisniti in dvigniti tako, da roko naslonite na naslonjalo stola ali jo uprete v steno.
Any unused medicine or waste material should be disposed of in accordance with local requirements. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Paediatric population There is no relevant indication for use of Zutectra in children under the age of 18. 
Ustrezne indikacije za uporabo zdravila Zutectra pri otrocih, starih manj kot 18 let, ni.
The other ingredients are glycine and water for injections. 
Drugi sestavini zdravila sta glicin in voda za injekcije.
No serious adverse reaction was reported. 
O resnih neželenih učinkih niso poročali.
Palpitations, cardiac discomfort Rare* 
Bolezni srca palpitacije, srčno nelagodje redki*
No serious adverse events were reported to be related to study medication. 
O resnih neželenih učinkih, povezanih s študijskim zdravilom, niso poročali.
If you are HBs antigen positive you will not receive Zutectra since there is no benefit in administering this medicine to you. 
Če ste HBs antigen pozitivni, zdravila Zutectra ne boste prejeli, ker od dajanja tega zdravila ne bi imeli nobene koristi.
Other medicines and Zutectra 
Druga zdravila in zdravilo Zutectra
Before preparing the injection, decide where you are going to inject. 
Pred pripravo injekcije se odločite, kam boste injicirali zdravilo.
- Take the syringe out of the pack. 
- Injekcijsko brizgo vzemite iz pakiranja.
SN: {number} [serial number] 
PC: {številka} [koda zdravila] SN: {številka} [serijska številka]
For the documentation of your injections of Zutectra it is strongly recommended to use the treatment diary. 
Za dokumentiranje dajanja injekcij zdravila Zutectra je zelo priporočljivo, da vodite dnevnik zdravljenja.
Your doctor will tell you how much and how often you need to use Zutectra. 
Zdravnik vam bo povedal, koliko in kako pogosto morate uporabljati zdravilo Zutectra.
In a local tolerance trial in rabbits, there was no evidence of irritation attributable to Zutectra. 
V preskušanjih lokalnega prenašanja na kuncih ni bilo dokazov o draženju, ki bi ga lahko pripisali zdravilu Zutectra.
Keep the container in the outer carton in order to protect from light. 
Vsebnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
- Examine the solution carefully. 
- Raztopino skrbno preglejte.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. 
Standardni ukrepi za preprečevanje okužb zaradi uporabe zdravil, pripravljenih iz človeške krvi ali plazme, vključujejo izbiro darovalcev, presejanje posameznih odvzetih enot in združene plazme za specifične označevalce okužbe ter vključevanje učinkovitih proizvodnih stopenj za inaktivacijo/odstranitev virusov.
These include - careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and - the testing of each donation and pools of plasma for signs of virus/infections. 
Ti ukrepi vključujejo: - skrbno izbiro darovalcev krvi in plazme, da se izključijo osebe s tveganjem prenosa okužbe in - testiranje vsake odvzete enote in združene plazme za znake virusov/okužb.
The ADRs reported in four trials are summarised and categorised according to the MedDRA system organ class and frequency below. 
Neželeni učinki, o katerih so poročali v teh štirih preskušanjih, so glede na organski sistem in pogostnost povzeti ter razporejeni po MedDRA klasifikaciji.
In very rare cases human normal immunoglobulins may cause a serious allergic reaction. 
zelo redkih primerih lahko normalni humani imunoglobulini povzročijo resne alergijske reakcije.
No other preparations may be added to the Zutectra solution as any change in the electrolyte concentration or the pH may result in precipitation or denaturisation of the proteins. 
K raztopini zdravila Zutectra ne smemo dodajati drugih pripravkov, ker bi vsaka sprememba koncentracije elektrolitov ali pH vrednosti lahko vodila v obarjanje ali denaturacijo beljakovin.
Your doctor will regularly check your condition and tell you how much and how often you need to use Zutectra. 
Vaš zdravnik bo vaše stanje redno preverjal in vam povedal, koliko zdravila Zutectra morate uporabiti in kako pogosto.
The safety of this medicinal product for use in breast-feeding has not been established in controlled clinical trials and therefore should only be given with caution to breast-feeding mothers. 
Varnosti tega zdravila za uporabo med dojenjem niso dokazali v kontroliranih kliničnih preskušanjih, zato ga je treba doječim materam dajati previdno.
Manufacturers of these medicines also include steps in the processing of the blood or plasma that can inactivate or remove viruses. 
Izdelovalci teh zdravil vključijo tudi stopnje priprave krvi in plazme, kjer se virusi inaktivirajo ali odstranijo.
The objectives of the open, prospective, single-arm clinical trial were the investigation of feasibility of home self-administration (including patient compliance), efficacy and safety of subcutaneous application of Zutectra in a population of stable patients during long-term treatment for prophylaxis against re-infection of a transplanted liver in 66 patients. 
Cilj odprtega, prospektivnega kliničnega preskušanja z enim krakom je bilo raziskati možnost samoinjiciranja doma (vključno s sodelovanjem bolnika), učinkovitost in varnost subkutane uporabe zdravila Zutectra pri populaciji stabilnih bolnikov med dolgoročnim zdravljenjem za preprečevanje ponovne okužbe presajenih jeter pri 66 bolnikih.
During the 48-weeks treatment phase constant serum HBs antibody concentrations ≥ 100 IU/l were measured in all patients at all assessments with mean values of 312.0 ± 103.5 IU/l at the end of the treatment period. 
V 48-tedenskem obdobju zdravljenja so izmerili konstantne koncentracije protiteles HBs v serumu ≥ 100 i.e./l pri vseh bolnikih v vseh ocenitvah s srednjimi vrednostmi 312,0 ± 103,5 i.e./l ob koncu obdobja zdravljenja.
Important: Do not use on any area where you can feel lumps, bumps, firm knots, pain or on an area that is discoloured, indented, scabbed, or where the skin is broken. 
Pomembno: Ne uporabljajte na predelu, kjer čutite zatrdline, bule, trdne vozliče, bolečino ali na predelu, ki je obarvan, vdrt, krastav ali kjer je koža poškodovana.
The following adverse reactions have been reported in the context of 4,810 subcutaneous applications of Zutectra during four completed clinical trials and 1,006 applications during a non-interventional post marketing safety study (PASS). 
Po 4.810 subkutanih uporabah zdravila Zutectra med štirimi zaključenimi kliničnimi preskušanji in 1.006 uporabah v neinterventnih študijah o varnosti zdravila po pridobitvi dovoljenja za promet
What Zutectra is and what it is used for What you need to know before you use Zutectra How to use Zutectra 
Kaj je zdravilo Zutectra in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Zutectra Kako uporabljati zdravilo Zutectra
Do not use solutions that are cloudy or have particles. 
Ne uporabljajte raztopine, ki so motne ali imajo delce.
Solutions that are cloudy or have deposits should not be used. 
Raztopin, ki so motne ali imajo usedline, ne smete uporabiti.
Zutectra can reduce the effectiveness of some vaccines (measles, rubella, mumps, chicken pox) for a period of up to 3 months. 
Zdravilo Zutectra lahko v obdobju do 3 mesecev zmanjšuje učinkovitost nekaterih cepiv (ošpice, rdečke, mumps, vodene koze).
In particular, patients naive to human normal immunoglobulin, patients switched from an alternative product or when there has been a long interval since the previous injection should be monitored during the first injection and for the first hour after the first injection, in order to detect potential adverse signs. 
Zlasti bolnike, ki še niso prejemali normalnega humanega imunoglobulina, bolnike, ki so prešli z alternativnega zdravila ali če je od prejšnjega injiciranja preteklo dalj časa, je treba spremljati med prvim injiciranjem in v prvi uri po prvem injiciranju, da se odkrijejo morebitni neželeni znaki.
The best places for injections are where the skin is loose and soft for example in the abdomen, arm, thigh or buttocks, and away from joints, nerves, bones. 
Najboljša mesta za injiciranje so tam, kjer je koža ohlapna in mehka, na primer na trebuhu, rokah, stegnu ali zadnjici in stran od sklepov, živcev in kosti.
If you have any further questions, ask your doctor or pharmacist. 
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
The non-interventional post authorization safety study (PASS 978) enrolled 61 adult patients ≥ 6 months after liver transplantation for hepatitis B induced liver failure. 
V neinterventno študijo o varnosti zdravila po pridobitvi dovoljenja za promet (PASS 978) je bilo vključenih 61 odraslih bolnikov ≥ 6 mesecev po presaditvi jeter zaradi s hepatitisom tipa B izzvane odpovedi jeter.
Biotest Medical, S.L.U. 
España Biotest Medical, S.L.U.
Do not use Zutectra - if you are allergic to human immunoglobulin or any of the other ingredients of this medicine (listed in section 6). 
Kaj morate vedeti, preden boste uporabili zdravilo Zutectra Ne uporabljajte zdravila Zutectra: če ste alergični na humani imunoglobulin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Precautions to be taken before handling or administering the medicinal product Injection of the medicinal product by the patient or by caregiver in a home treatment requires training by a physician experienced in the guidance of patients for home treatment. 
Injiciranje zdravila s strani bolnika ali negovalnega osebja ob zdravljenju na domu zahteva usposabljanje, ki naj ga vodi zdravnik z izkušnjami pri vodenju bolnikov, ki se zdravijo doma.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. 
Pri zdravilih, ki se izdelajo iz človeške krvi ali plazme, se izvajajo določeni ukrepi za preprečevanje prenosa okužb na bolnike.
Name and address of the manufacturer of the biological active substance 
Ime in naslov izdelovalca biološke zdravilne učinkovine
No fatal case was observed during the study. 
V času študije ni bilo smrtnih primerov.
Most side effects observed with Zutectra were mild to moderate in nature. 
Večina neželenih učinkov, ki so jih opazili z zdravilom Zutectra, je bilo blage do zmerne narave.
- Hold the syringe with the needle pointing upwards, and tap the syringe gently with your fingers until the air has collected at the tip. 
- Injekcijsko brizgo držite z iglo obrnjeno navzgor in s prsti nežno trkajte po brizgi, dokler se ves zrak ne zbere tik pod vrhom.
Immunoglobulins like Zutectra have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective. 
Imunoglobulini, kot je zdravilo Zutectra, niso bili povezani z okužbami s hepatitisom A ali parvovirusom B19 verjetno zato, ker so protitelesa proti tem okužbam, ki so vsebovana v zdravilu, zaščitna.
Immunoglobulins are normal constituents of the human body, therefore toxicity testing in heterologous species is of no relevance. 
5.3 Predklinični podatki o varnosti Imunoglobulini so normalna sestavina človeškega telesa, zato testiranje njihove toksičnosti na heterolognih vrstah nima pomena.
Then pull the needle out immediately and let go of the pinched skin. 
Nato takoj izvlecite iglo in sprostite stisk na koži.
Aquilant Pharmaceuticals 21 Fonthill Business Park Fonthill Road Clondalkin 
21 Fonthill Business Park Fonthill Road
Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coombs' test). 
A, B, D, lahko ovira nekatere serološke teste na protitelesa proti rdečim krvnim celicam, na primer antiglobulinski test (Coombsov test).
Inject the liquid by pressing gently on the plunger. 
Tekočino injicirajte z nežnim pritiskom na bat.
Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines such as rubella, mumps, measles and varicella for a period of 3 months. 
Dajanje imunoglobulinov lahko vpliva na razvoj imunskega odgovora na živa atenuirana virusna cepiva, kot so cepivo proti rdečkam, mumpsu, ošpicam in noricam (varicella), v obdobju 3 mesecev.
Zutectra contains 150 mg/ml of human plasma protein of which at least 96 % is immunoglobulin G (IgG). 
Zdravilo Zutectra vsebuje 150 mg/ml humanega plazemskega proteina, od katerega je najmanj 96 % imunoglobulina G (IgG).
A sufficient surveillance period with stable anti-HBs trough serum levels of > 100 IU/l as well as a fixed dosage regimen is required: the monitoring schedule of patients anti-HBs antibody levels (see above) needs to be closely followed. 
Potrebno je ustrezno obdobje nadzora s stabilnimi najnižjimi serumskimi ravnmi anti-HBs > 100 i.e./l in fiksna odmerna shema: natančno je treba upoštevati načrt spremljanja ravni protiteles anti-HBs pri bolnikih (glejte zgoraj).
Potential complications can often be avoided by ensuring that patients: are not sensitive to human normal immunoglobulin, by initially injecting the product slowly; are carefully monitored for any symptoms throughout the injection. 
Morebitnim zapletom se je pogosto mogoče izogniti z zagotavljanjem, da: da bolniki niso preobčutljivi na normalni humani imunoglobulin; na začetku naj se zdravilo injicira počasi;
If you are administering Zutectra yourself, please read instructions in the section “How to inject Zutectra by yourself or by caregiver” carefully. 
Če si boste zdravilo Zutectra dajali sami, natančno preberite navodila v poglavju »Samoinjiciranje zdravila Zutectra ali injiciranje s strani negovalnega osebja«.
Zutectra contains antibodies against the hepatitis B virus which are the body's own defensive substances to protect you from hepatitis B. Hepatitis B is an inflammation of the liver caused by the hepatitis B virus. 
Zdravilo Zutectra vsebuje protitelesa proti virusu hepatitisa tipa B, ki so telesu lastne obrambne snovi za zaščito pred hepatitisom tipa B. Hepatitis tipa B je vnetje jeter, ki ga povzroča virus hepatitisa tipa B.
The maximum IgA content is 6,000 micrograms/ml. 
Največja vsebnost IgA je 6.000 mikrogramov/ml.
Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. 
Ob sumu na reakcije alergijskega ali anafilaktičnega tipa je treba injiciranje takoj prekiniti.
The weekly subcutaneous dose was 500 IU for patients with bodyweight < 75 kg (a dose increase to 1000 IU was allowed, if medically required to maintain a safety level of > 100 IU) and 1000 IU for patients with bodyweight ≥ 75 kg. 2 patients received a higher and 2 patients received a lower dose than recommended by the weight based dosing regimen. 
Tedenski subkutani odmerek je bil 500 i.e. pri bolnikih s telesno maso < 75 kg (dovoljeno je bilo zvišanje odmerka do 1.000 i.e., če je obstajala medicinsko utemeljena potreba za zagotovitev varnostne ravni > 100 i.e.) in 1.000 i.e. pri bolnikih s telesno maso ≥ 75 kg. 2 bolnika sta prejela večji, 2 pa manjši odmerek od priporočenega režima odmerjanja glede na telesno maso.
Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration. 
Redko humani normalni imunoglobulini lahko izzovejo nenaden padec krvnega tlaka in v izoliranih primerih anafilaktični šok, in to celo v primerih, ko pri predhodnem dajanju zdravila bolnik ni pokazal preobčutljivosti.
Driving and using machines Zutectra has no or negligible effects on your ability to drive or use machines. 
Zdravilo Zutectra nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
You can inject Zutectra yourself without the help of your doctor, if they have trained you to do this. 
Samoinjiciranje zdravila ali injiciranje s strani negovalnega osebja Zdravilo Zutectra si lahko injicirate sami, brez pomoči vašega zdravnika, če ste bili o tem ustrezno poučeni.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Cepiva, pripravljena iz živih oslabljenih virusov
In total, 53/66 patients (80.3 %) used antiviral medication and 13 patients received monotherapy with Zutectra during this study. 
Skupaj je v tej študiji 53/66 bolnikov (80,3 %) uporabljalo protivirusna zdravila in 13 bolnikov je prejelo monoterapijo z zdravilom Zutectra.
However, if you have used more than the prescribed dose of Zutectra, contact your doctor, healthcare professional or pharmacist straight away for advice. 
Vseeno se v primeru, da ste uporabili večji odmerek zdravila Zutectra, kot vam je bilo predpisano, po nasvet takoj obrnite na svojega zdravnika, strokovnega zdravstvenega delavca ali farmacevta.
The maximum immunoglobulin A (IgA) content is 6,000 micrograms/ml. 
Največja vsebnost imunoglobulina A (IgA) je 6.000 mikrogramov/ml.
Zutectra must not be administered intravascularly. 
Zdravila Zutectra se ne sme dajati intravaskularno.
Frequency per injection has been evaluated using the following criteria: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare 
Pogostnost v povezavi s posameznim injiciranjem je bila ovrednotena po naslednjih kriterijih: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do
It's harder to give yourself an injection here. 
Tukaj si le težko sami injicirate.
Serum anti-HBs antibody levels should be measured at least every 2-4 weeks and at the discretion of the physician in charge for at least half a year. 
Serumske ravni protiteles anti-HBs je treba vsaj pol leta meriti najmanj vsake 2 do 4 tedne po presoji lečečega zdravnika.
The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women. 
Varnosti uporabe zdravila v nosečnosti v nadzorovanih kliničnih preskušanjih na ljudeh niso raziskali, zato ga je treba pri nosečnicah uporabljati previdno.
An allergic reaction may include sudden wheeziness, difficulty in breathing, fast pulse, swelling of the eyelids, face, lips, throat or tongue, rash or itching. 
Alergijska reakcija lahko vključuje nenadno sopenje, težave pri dihanju, hiter srčni utrip, zatekanje vek, obraza, ustnic, žrela ali jezika, izpuščaj ali srbenje.
One ml solution in a pre-filled syringe (Type I glass) with a stopper (bromobutyl) and a tip cap (bromobutyl rubber). 
En ml raztopine v napolnjeni injekcijski brizgi (steklo tipa I) z zamaškom (bromobutil) in snemljivo zaporko (bromobutilna guma).
Serum antiHBs trough levels of 100 IU/l and higher (primary efficacy endpoint) were maintained for all patients during the 18 to 24 week trial period. 
Najnižje serumske anti-HBs ravni 100 i.e./l in več (primarno merilo učinkovitosti) so se v 18-24 tednih trajanja preskušanja ohranile pri vseh bolnikih.
No treatment failures occurred during the 6month study period. 
V 6-mesečnem obdobju študije ni bilo nobenega primera neuspešnega zdravljenja.
Do not use this medicine after the expiry date which is stated on the outer carton and the syringe label after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na injekcijski brizgi poleg oznake Uporabno do:.
The > 100 IU/l safety margin is the generally accepted level of effective prevention against HBV re-infection in liver transplant patients at risk. 
Varnostna mejna vrednost > 100 i.e./l je splošno sprejeta raven učinkovitega preprečevanja ponovne okužbe z virusom hepatitisa tipa B (HBV) pri bolnikih s presajenimi jetri, ki so izpostavljeni tveganju.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. 
Ukrepi, ki se izvajajo, so morda manj učinkoviti proti virusom brez ovojnice, kot je parvovirus B19.
In total, 42/61 patients (68.9 %) used antiviral medication and 19 patients received monotherapy with Zutectra during this study. 
Skupaj je v tej študiji 42/61 bolnikov (68,9 %) uporabljalo protivirusna zdravila in 19 bolnikov je prejelo monoterapijo z zdravilom Zutectra.
LIST OF EXCIPIENTS Excipients: Glycine, water for injections. 
SEZNAM POMOŽNIH SNOVI Pomožne snovi: glicin, voda za injekcije.
Prepare the Zutectra syringe: 
Pripravite injekcijsko brizgo zdravila Zutectra:
Serum HBs antibody concentrations above the minimum safety trough level of >100 IU/L were measured in all patients at all timepoints independent of the type of administration (investigator, caregiver or self-injection), the dose regimen (500 IU, 1000 IU, 1500 IU) or the treatment intervals. 
Pri vseh bolnikih so na vseh časovnih točkah izmerili serumske koncentracije protiteles HBs nad najnižjo varnostno ravnjo > 100 i.e./l, neodvisno od vrste aplikacije (raziskovalec, negovalec ali samoinjiciranje), režim odmerjanja (500 i.e., 1.000 i.e., 1.500
Zutectra is presented as a solution for injection provided in pre-filled syringes (500 IU/ml - pack size of 5 in a blister). 
Zdravilo Zutectra je na voljo v obliki raztopine za injiciranje v napolnjenih injekcijskih brizgah (500 i.e./ml - pakiranje po 5 v pretisnem omotu).
Do not use Zutectra if you notice that the solution is cloudy or has particles. 
Ne uporabljajte zdravila Zutectra, če opazite, da je raztopina motna ali da so v njej prisotni delci.
What Zutectra looks like and the contents of the pack 
Izgled zdravila Zutectra in vsebina pakiranja
Keep the syringes and syringe disposal unit out of the reach of children; lock the supplies if possible. 
Injekcijske brizge in zabojček, kamor odvržete uporabljene brizge, hranite zunaj dosega otrok; po možnosti jih zaklenite.
HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. 
Negativni status HBV-DNK je treba potrditi v 3 mesecih pred ortotopno presaditvijo jeter.
Avoid using the belt line area, as rubbing may irritate the injection site. 
Izogibajte se predelu pasu, ker drgnjenje lahko draži mesto injiciranja.
Rarely, human hepatitis B immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who have tolerated previous treatment with human immunoglobulin. 
V redkih primerih lahko humani imunoglobulin proti hepatitisu tipa B povzroči padec krvnega tlaka z anafilaktično reakcijo, in sicer celo pri bolnikih, ki so predhodno zdravljenje s humanimi imunoglobulini dobro prenašali.
Pharmacotherapeutic group: Immune sera and immunoglobulins, Specific immunoglobulins, Hepatitis B immunoglobulin 
Farmakoterapevtska skupina: imunski serumi in imunoglobulini, specifični imunoglobulini, imunoglobulin hepatitisa B
One pre-filled syringe of 1 ml Zutectra contains 500 IU. 
Ena 1-mililitrska napolnjena injekcijska brizga zdravila Zutectra vsebuje 500 i.e.
Arms: The back of the upper arm should be used. 
Roke: Uporabite zadnjo stran nadlakti.
It is much easier for someone else to use this site if you do need help. 
Če potrebujete pomoč, je veliko preprosteje, če to mesto za injiciranje uporabi kdo drug.